An economic evaluation of varicella vaccination in Italian adolescents

Vaccine

Volumn 22, Issue 27-28, 2004, Pages 3546-3562

  Thiry, Nancy ^a   Beutels, Philippe ^a,b   Tancredi, Francesco ^c   Romanò, Luisa ^d   Zanetti, Alessandro ^d   Bonanni, Paolo ^e   Gabutti, Giovanni ^f   Damme, Pierre Van ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b SYDNEY CHILDREN'S HOSPITAL   (Australia)

^c ASL NA 4   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF FLORENCE   (Italy)

^f UNIVERSITY OF SALENTO   (Italy)

Author keywords

Adolescents; Chickenpox; Cost effectiveness; Modeling; Varicella history

Indexed keywords

CHICKENPOX VACCINE;

ACCURACY; ADOLESCENT; ARTICLE; BLOOD ANALYSIS; BUDGET; CHICKENPOX; CHILD; COHORT ANALYSIS; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH PROGRAM; HUMAN; ITALY; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PROBABILITY; SENSITIVITY AND SPECIFICITY; SEROLOGY; SIMULATION; SOCIETY; VACCINATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; COST-BENEFIT ANALYSIS; ENCEPHALITIS, VARICELLA ZOSTER; FEMALE; HOSPITALIZATION; HUMANS; INFANT; ITALY; MALE; MARKOV CHAINS; MASS IMMUNIZATION; MIDDLE AGED;

EID: 4243073121     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.03.043     Document Type: Article

References (63)

1. Gershon AA, Takahashi M, White CJ. Varicella Vaccine. In: Plotkin SA, Orenstein WA, editors. Vaccines, 3rd ed. Philadelphia: W.B. Sounders Co, 1999. p. 475-507.
2. Choo P.W., Donahue J.G., Manson J.E., Platt R. The epidemiology of varicella and its complications. J. Infect. Dis. 172:1995;706-712
3. Jaeggi A., Zurbruegg R.P., Aebi C. Complications of varicella in a defined central European population. Arch. Dis. Child. 79:1998;472-477
4. Scuffham P.A., Lowin A.V., Burgess M.A. The cost-effectiveness of varicella vaccine programs for Australia. Vaccine. 18(5-6):2000;407-415
5. Meyer P.A., Seward J.F., Jumaan A.O., Wharton M. Varicella mortality: Trends before vaccine licensure in the United States, 1970-1994. JID. 182(2):2000;383-390
6. Preblud S.R. Varicella: complications and costs. Pediatrics. 78:1986;728-735
7. Guess H.A., Broughton D.D., Melton L.J., Kurland L.T. Population based studies of varicella complications. Pediatrics. 78:1986;723-727
8. Izurieta H.S., Strebel P.M., Blake P.A. Postlicensure effectiveness of varicella vaccine during an outbreak in a child care centre. JAMA. 278(18):1997;1495-1499
9. Skull S.A., Wang E.L. Varicella vaccination - a critical review of the evidence. Arch. Dis. Child. 85:2001;83-90
10. Vázquez M., LaRussa P.S., Gershon A.A., Steinberg S.P., Freudigman K., Shapiro E.D. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. 344(13):2001;955-960
11. Wise R.P., Salive M.E., Braun M.M., et al. Postlicensure safety surveillance for varicella vaccine. JAMA. 284(10):2000;1271-1279
12. Weibel R.E., Neff B.J., Kuter B.J., et al. Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N. Engl. J. Med. 310(22):1984;1409-1415
13. Seward J.F., Watson B.W., Peterson C.L., et al. Varicella disease after introduction of varicella vaccine in the United States. 1995-2000. JAMA. 287:2002;606-611
14. Halloran E. Epidemiologic effects of varicella vaccination. Infect. Dis. Clin. North Am. 10(3):1996;631-655
15. Brisson M., Gay N.J., Edmunds W.J., Andrews N.J. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine. 20(19-20):2002;2500-2507
16. Garnett G.P., Grenfell B.T. The epidemiology of varicella-zoster virus infections: the influence of varicella on the prevalence of herpes zoster. Epidemiol. Infect. 108:1992;513-528
17. Thomas S.L., Wheeler J.G., Hall A.J. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet. 360:2002;678-682
18. Romanò L., Grilli G., Zanetti A.R. Sieroepidemiologia della varicella in una coorte di adolescenti italiani. Ann. Ig. 14(suppl 6):2002;7-10
19. Bonanni P. Italie-la politique de vaccination. Vax. Info. 36:2003;6-8
20. Salmaso S., Mandolini D., Scalia Tomba G., Esposito N. La prevenzione della varicella in Italia: strategie di vaccinazione. Ann. Ig. 14(suppl 6):2002;35-44
21. Fleck F. UK and Italy have low MMR uptake. BMJ. 327:2003;1124
22. Thiry N., Beutels P., Van Damme P., Van Doorslaer E. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics. 21(1):2003;13-38
23. Hanslik T., Boëlle P.Y., Schwarzinger M., et al. Varicella in French adolescents and adults: individual risk assessment and cost-effectiveness of routine vaccination. Vaccine. 21:2003;3614-3622
24. Lieu T.A., Finkler L.J., Sorel M.E., Black S.B., Shinefield H.R. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents. Pediatrics. 95(5):1995;632-638
25. Istituto Nazionale di Statistica. Internet site. URL: http://www.istat.it/index.htm [accessed on 2003].
26. Gold MR, Siegel JE, Russel LB, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.
27. Gabutti G., Penna C., Rossi M., et al. The seroepidemiology of varicella in Italy. Epidemiol. Infect. 126:2001;433-440
28. Grenfell B.T., Anderson R.M. The estimation of age-related rates of infections from case notifications and serological data. J. Hyg. Camb. 95:1985;419-436
29. Giaquinto C., Sturkenboom M., Mannino S., Arpinelli F., Nicolosi A., Cantarutti L. Epidemiologia ed esiti della varicella in Italia: risultati di uno studio prospettico sui bambini (0-14 anni) seguiti dai pediatri di libera scelta (Studio Pedianet). Ann. Ig. 14(suppl 6):2002;21-27
30. Zotti C.M., Maggiorotto G., Migliardi A. I costi della varicella. Ann. Ig. 14(suppl 6):2002;29-33
31. Färkkilä M., Koskiniemi M., Leikola M., Vaheri A. Twenty-five year epidemiology of acute encephalitis in southern Finland. Neurol. Infect. Epidemiol. 2:1997;25-31
32. Brisson M., Edmunds W.J., Gay N.J., Law B., De Serres G. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine. 18:2000;2775-2778
33. Ampofo K., Saiman L., LaRussa P., Steinberg S., Annunziato P., Gershon A. Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin. Infect. Dis. 34(6):2002;774-779
34. Watson B.M., Piercy S.A., Plotkin S.A., Starr S.E. Modified chickenpox in children immunized with the Oka/Merck varicella vaccine. Pediatrics. 91(1):1993;17-22
35. Lucioni C., Ciriminna S., Di Carlo P., Mazzi S., Serra G., Titone L. Il costo sociale del morbillo in eta pediatrica. L'epidemia a Palermo nel 1996-1997. Pharmacoecon. Italian Res. Art. 1(1):1999;17-33
36. Coudeville L, Brunot A, Dervaux B. Varicella vaccination in Italy: an economic evaluation of different scenarios. Poster Presented at the 21st Espid Annual Meeting, Taormina, Sicily, 9-12 April 2003.
37. Fornaro P., Gandini F., Marin M., et al. Epidemiology and cost analysis of varicella in Italy: results of a sentinel study in the pediatric practice. Pediatr. Infect. Dis. J. 18:1999;414-419
38. Li S., Chan I.S.F., Matthews H., et al. Inverse relationship between six-week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr. Infect. Dis. J. 21:2002;337-342
39. White C.J., Kuter B.J., Ngai A., et al. Modified cases of chickenpox after varicella vaccination: correlation of protection with antibody response. Pediatr. Infect. Dis. J. 11:1992;19-23
40. Italian Ministry of Health. Internet site. URL: http://www. ministerosalute.it [accessed on 2002].
41. Lieu T.A., Cochi S.L., Black S.B., et al. Cost-effectiveness of a routine varicella vaccination program for US children. JAMA. 271(5):1994;375-381
42. Beutels P, Van Damme P, Van Doorslaer E. Program Evaluation of Universal Varicella Vaccination in Belgium. ESOC-report no. 36, University of Antwerp-UIA, September 2000.
43. Beutels P., Van Damme P., Van Casteren V., Gay N.J., De Schrijver K., Mehus A. The difficult quest for data on "vanishing" vaccine-preventable infections in Europe: the case of measles in Flanders (Belgium). Vaccine. 20:2002;3551-3559
44. Gruppo di lavoro ICONA. Indagine nazionale sulla copertura vaccinale infantile. Rapporto ISTISAN (Istituto Superiore di Sanita), vol. 98/33 (viii), 1998, p. 123.
45. Lucioni C., Criminna S., Mazzi S. Measles vaccination policy in Palermo (Sicily) in the mid nineties: a cost-benefit evaluation. Journal of Preventive Med. Hyg. 41:2000;1-12
46. Sullivan-Bolyai J.Z., Yin E.K., Cox P., et al. Impact of chickenpox on households of healthy children. Pediatr. Infect. Dis. J. 6:1987;33-35
47. Coudeville L., Paree F., Lebrun T., Sailly J.-C. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine. 17(2):1999;142-151
48. Díez Domingo J., Aristegui J., Calbo F., et al. Epidemiology and economic impact of varicella in immunocompetent children in Spain. Vaccine. 21:2003;3236-3239
49. Díez Domingo J., Ridao M., Latour J., Ballester A., Morant A. A cost benefit analysis of routine varicella vaccination in Spain. Vaccine. 17(11-12):1999;1306-1311
50. Huse D.M., Meissner H.C., Lacey M.J., Oster G. Childhood vaccination against chickenpox: an analysis of benefits and costs. J. Pediatr. 124(6):1994;869-874
51. Wutzler P., Neiss A., Banz K., Goertz A., Bisanz H. Can varicella be eliminated by vaccination? Potential clinical and economic effects of universal childhood varicella vaccination in Germany. Med. Microbiol. Immunol. 191:2002;89-96
52. Brisson M., Edmunds W.J. The cost-effectiveness of varicella vaccination in Canada. Vaccine. 20:2002;1113-1125
53. Beutels P., Clara R., Tormans G., Van Doorslaer E., Van Damme P. Costs and benefits of routine varicella vaccination in German children. J. Infect. Dis. 174(suppl 3):1996;335-341
54. Preblud S.R., Orenstein W.A., Koplan J.P., Bart K.J., Hinman A.R. A benefit-cost analysis of a childhood varicella vaccination programme. Postgrad. Med. J. 61(suppl 4):1985;17-22
55. Laurent P., Coudeville L., Lebrun T., Sailly J.C., Parée F., Buisset C. Evaluation à l'occasion d'une enquête sur les conséquences de la varicella, d'un indicateur d'absentéisme professionnel le congé enfant malade. Arch. Mal. Prof. 58(5):1997;449-454
56. Johannesson M., Weinstein M.C. On the decision rules of cost-effectiveness analysis. J. Health Econ. 12(4):1993;459-467
57. Tugwell B.D., Lee L.E., Gillette H., et al. Chickenpox outbreak in a highly vaccinated school population. Pediatrics. 113(3):2004;455-459
58. Banz K., Wagenpfeil S., Neiss A., et al. The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine. 21:2003;1256-1267
59. Profetta M.L., Ferrante P., Mendogni D. Correlazione tra riscontri sierologici e dati anamnestici nell'ambito delle principali malattie virali dell'infanzia. Boll. Ist Sieroter. 66(5):1987;367-376
60. Getsios D., Caro J.J., Caro, De Wals P., Law B.J., Robert Y. Lance J-AAR. Instituting a routine varicella vaccination program in Canada: an economic evaluation. Pediatr. Infect. Dis. J. 21:2002;542-547
61. Krause P.R., Klinman D.M. Varicella vaccination: evidence for frequent reactivation of the vaccine strain in healthy children. Nat. Med. 6:2000;1299-1300
62. Beutels P., Edmunds W.J., Antonanzas F., et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics. 20(1):2002;1-7
63. Thiry N., Beutels P., Van Damme P., Van Doorslaer E. Economic evaluation of varicella vaccination programmes: a review of the literature. The authors' reply. Pharmacoeconomics. 22(2):2004;136-138